Evaluation of the concomitant use of oral preventive treatments and onabotulinumtoxinA in chronic migraine: the PREVENBOX study.
Alicia AlpuenteV J GallardoM Torres-FerrúsS Santos-LasaosaA L GuerreroJ M LaínezJ VigueraA Gago-VeigaP IrimiaM Sánchez Del RioP Pozo-RosichPublished in: European journal of neurology (2020)
Our study demonstrated the efficacy and safety of onabotulinumtoxinA. This treatment reduced the use of oral prophylactics. Withdrawal of oral prophylactics was most likely to occur after five cycles of treatment.
Keyphrases